 BOULDER, Colo., March 11, 2020 GLOBE NEWSWIRE -- miRagen Therapeutics, Inc. MGEN, today reported operating highlights and financial results for the quarter and full-year ended December 31, 2019 and provided an outlook for 2020. This change from assessing overall response to skin response was driven by the fact that patients allowed into the study only have skin disease and are verified not to have blood, nodes, or visceral involvement at study entry. 